Kontafarma China Holdings (HKSE:01312) 5-Year EBITDA Growth Rate : -28.40% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings 5-Year EBITDA Growth Rate?

Kontafarma China Holdings's EBITDA per Share for the six months ended in Dec. 2023 was HK$-0.01.

During the past 12 months, Kontafarma China Holdings's average EBITDA Per Share Growth Rate was 100.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -24.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -28.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kontafarma China Holdings was 178.10% per year. The lowest was -57.60% per year. And the median was -24.10% per year.

Competitive Comparison of Kontafarma China Holdings's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kontafarma China Holdings's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kontafarma China Holdings's 5-Year EBITDA Growth Rate falls into.

Kontafarma China Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Kontafarma China Holdings (HKSE:01312) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Kontafarma China Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kontafarma China Holdings (HKSE:01312) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG

Website

https://www.kontafarma.com.hk

Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.

Executives

Ning Bo Bao Shui Qu San Jin Guo Tou Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Shan Xi Jiao Tong Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Jian She Tou Zi Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Ren Min Zheng Fu Guo You Zi Chan Jian Du Guan Li Wei Yuan Hui	2201 Interest of corporation controlled by you
Shan Xi Sheng Gao Su Gong Lu Ji Tuan You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Shan Xi Sheng Guo You Zi Ben Yun Ying You Xian Gong Si Qian Cheng Shan Xi Sheng Guo You Zi Ben Tou Z	2201 Interest of corporation controlled by you
China Health Management Investment Limited	2101 Beneficial owner
Waranty Assets Management (hk) Limited	2201 Interest of corporation controlled by you
Shen Zhen Shi Hua Rong Tai Zi Chan Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Resuccess Investments Limited
Thtf Energy-saving Holdings Limited

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines